Re: "Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial" by Crippa et al

Cannabis Cannabinoid Res. 2022 Apr;7(2):231-233. doi: 10.1089/can.2022.0034. Epub 2022 Apr 1.

Authors

Luis Vitetta^{1

2}, Tomas Andersen², Michelle Quezada², Dave Rutolo², Jeremy D Henson^{2

3}

Affiliations

¹ Department of Pharmacology, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
² Research Department, Medlab Clinical Ltd., Sydney, Australia.
³ Department of Medicine, Prince of Wales Clinical School, University of NSW, Sydney, Australia.

No abstract available

Publication types

Letter
Randomized Controlled Trial
Comment

MeSH terms

COVID-19 Drug Treatment*
Cannabidiol*
Double-Blind Method
Humans
SARS-CoV-2

Substances

Cannabidiol